↓ Skip to main content

Biomarkers for Alzheimer’s Disease Drug Development

Overview of attention for book
Cover of 'Biomarkers for Alzheimer’s Disease Drug Development'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Epidemiology of Dementia: The Burden on Society, the Challenges for Research
  3. Altmetric Badge
    Chapter 2 Population-Based Approaches to Alzheimer’s Disease Prevention
  4. Altmetric Badge
    Chapter 3 Systems Biology Methods for Alzheimer’s Disease Research Toward Molecular Signatures, Subtypes, and Stages and Precision Medicine: Application in Cohort Studies and Trials
  5. Altmetric Badge
    Chapter 4 CSF Lipidomics Analysis: High-Resolution Mass Spectrometry Analytical Platform
  6. Altmetric Badge
    Chapter 5 CSF N-Glycomics Using MALDI MS Techniques in Alzheimer’s Disease
  7. Altmetric Badge
    Chapter 6 MicroRNA Profiling of Alzheimer’s Disease Cerebrospinal Fluid
  8. Altmetric Badge
    Chapter 7 Validation of a Chemiluminescence Immunoassay for Measuring Amyloid-β in Human Blood Plasma
  9. Altmetric Badge
    Chapter 8 Mass Spectrometry-Based Metabolomic Multiplatform for Alzheimer’s Disease Research
  10. Altmetric Badge
    Chapter 9 Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases
  11. Altmetric Badge
    Chapter 10 Functional Magnetic Resonance Imaging in Alzheimer’ Disease Drug Development
  12. Altmetric Badge
    Chapter 11 Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies
  13. Altmetric Badge
    Chapter 12 Hybrid PET-MRI in Alzheimer’s Disease Research
  14. Altmetric Badge
    Chapter 13 Amyloid PET Imaging: Standardization and Integration with Other Alzheimer’s Disease Biomarkers
  15. Altmetric Badge
    Chapter 14 The Use of 18F-FDG PET in the Diagnostic Workup of Alzheimer’s Dementia
  16. Altmetric Badge
    Chapter 15 Quantification of Tau Load in Alzheimer’s Disease Clinical Trials Using Positron Emission Tomography
  17. Altmetric Badge
    Chapter 16 Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach
  18. Altmetric Badge
    Chapter 17 Unbiased Lipidomics and Metabolomics of Human Brain Samples
  19. Altmetric Badge
    Chapter 18 Neuropathological Assessment as an Endpoint in Clinical Trial Design
  20. Altmetric Badge
    Chapter 19 Analysis of Micro-RNA Expression by qPCR on a Microfluidics Platform for Alzheimer’s Disease Biomarker Discovery
  21. Altmetric Badge
    Chapter 20 Telomere Length Shortening in Alzheimer’s Disease: Procedures for a Causal Investigation Using Single Nucleotide Polymorphisms in a Mendelian Randomization Study
  22. Altmetric Badge
    Chapter 21 Quantifying miRNA Deregulation in Alzheimer’s Disease
  23. Altmetric Badge
    Chapter 22 Imaging of Microglial Activation in Alzheimer’s Disease by [11C]PBR28 PET
  24. Altmetric Badge
    Chapter 23 In Vivo Two-Photon Calcium Imaging of Hippocampal Neurons in Alzheimer Mouse Models
  25. Altmetric Badge
    Chapter 24 Cognitive Assessment in Alzheimer’s Disease Clinical Trials
  26. Altmetric Badge
    Chapter 25 Data Mining and Machine Learning Methods for Dementia Research
Attention for Chapter 1: Epidemiology of Dementia: The Burden on Society, the Challenges for Research
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter
5 X users

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
58 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Epidemiology of Dementia: The Burden on Society, the Challenges for Research
Chapter number 1
Book title
Biomarkers for Alzheimer’s Disease Drug Development
Published in
Methods in molecular biology, January 2018
DOI 10.1007/978-1-4939-7704-8_1
Pubmed ID
Book ISBNs
978-1-4939-7703-1, 978-1-4939-7704-8
Authors

Frank J. Wolters, M. Arfan Ikram

Abstract

Dementia is among the leading causes of death and disability. Due to the ageing population, its prevalence is expected to nearly triple worldwide by 2050, urging the development of preventive and curative interventions. Various modifiable risk factors have been identified in community-based cohort studies, but insight into the underlying pathophysiological mechanisms is lacking. Clinical trials have thus far failed in the development of disease-modifying therapy in patients with dementia, thereby triggering a shift of focus toward the presymptomatic phase of disease. The extensive preclinical disease course of Alzheimer's disease warrants reliable, easily obtainable biomarkers to aid in timely application of preventive strategies, selecting participants for neuroprotective trials, and disease monitoring in trials and clinical practice. Biomarker and drug discovery may yield the fruits from technology-driven developments in the field of genomics, epigenetics, metabolomics, and brain imaging. In that context, bridging the gap between translational and population research may well prove a giant leap toward development of successful preventive and curative interventions against dementia.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 58 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 9 16%
Student > Bachelor 7 12%
Student > Master 5 9%
Researcher 5 9%
Professor 4 7%
Other 5 9%
Unknown 23 40%
Readers by discipline Count As %
Neuroscience 6 10%
Agricultural and Biological Sciences 5 9%
Medicine and Dentistry 4 7%
Pharmacology, Toxicology and Pharmaceutical Science 4 7%
Social Sciences 3 5%
Other 11 19%
Unknown 25 43%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 March 2018.
All research outputs
#6,864,075
of 23,026,672 outputs
Outputs from Methods in molecular biology
#2,054
of 13,170 outputs
Outputs of similar age
#137,739
of 442,363 outputs
Outputs of similar age from Methods in molecular biology
#194
of 1,499 outputs
Altmetric has tracked 23,026,672 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 13,170 research outputs from this source. They receive a mean Attention Score of 3.4. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 442,363 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 1,499 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.